BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1611 related articles for article (PubMed ID: 17077359)

  • 21. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
    Rydén L; Landberg G; Stål O; Nordenskjöld B; Fernö M; Bendahl PO
    Breast Cancer Res Treat; 2008 May; 109(2):351-7. PubMed ID: 17636399
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment.
    Colleoni M; Viale G; Zahrieh D; Pruneri G; Gentilini O; Veronesi P; Gelber RD; Curigliano G; Torrisi R; Luini A; Intra M; Galimberti V; Renne G; Nolè F; Peruzzotti G; Goldhirsch A
    Clin Cancer Res; 2004 Oct; 10(19):6622-8. PubMed ID: 15475452
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
    Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
    J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oestrogen and progesterone receptor determinations in breast cancer: technology and biology.
    Thorpe SM; Rose C
    Cancer Surv; 1986; 5(3):505-25. PubMed ID: 3555780
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simultaneous immunohistochemical and biochemical hormone receptor assessment in breast cancer provides complementary prognostic information.
    Biesterfeld S; Schröder W; Steinhagen G; Koch R; Veuskens U; Schmitz FJ; Handt S; Böcking A
    Anticancer Res; 1997; 17(6D):4723-9. PubMed ID: 9494596
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy.
    Filipits M; Rudas M; Heinzl H; Jakesz R; Kubista E; Lax S; Schippinger W; Dietze O; Greil R; Stiglbauer W; Kwasny W; Nader A; Stierer M; Gnant MF;
    Clin Cancer Res; 2009 Sep; 15(18):5888-94. PubMed ID: 19723645
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Prognostic and therapeutic significance of steroid receptors in invasive breast cancer].
    Wyss P; Rageth JC; Unger C; Hochuli E
    Geburtshilfe Frauenheilkd; 1992 Oct; 52(10):611-6. PubMed ID: 1294437
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunohistochemical staining of estrogen and progesterone receptors: aspects for evaluating positivity and defining the cutpoints.
    Jalava P; Kuopio T; Huovinen R; Laine J; Collan Y
    Anticancer Res; 2005; 25(3c):2535-42. PubMed ID: 16080489
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Can expression of apoptosis genes, bcl-2 and bax, predict survival and responsiveness to chemotherapy in node-negative breast cancer patients?
    Kymionis GD; Dimitrakakis CE; Konstadoulakis MM; Arzimanoglou I; Leandros E; Chalkiadakis G; Keramopoulos A; Michalas S
    J Surg Res; 2001 Aug; 99(2):161-8. PubMed ID: 11469882
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer.
    Petit T; Wilt M; Velten M; Rodier JF; Fricker JP; Dufour P; Ghnassia JP
    Breast Cancer Res Treat; 2010 Nov; 124(2):387-91. PubMed ID: 20824324
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
    Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
    Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
    J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial.
    Adjuvant Breast Cancer Trials Collaborative Group
    J Natl Cancer Inst; 2007 Apr; 99(7):506-15. PubMed ID: 17405995
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy.
    Honma N; Horii R; Iwase T; Saji S; Younes M; Takubo K; Matsuura M; Ito Y; Akiyama F; Sakamoto G
    J Clin Oncol; 2008 Aug; 26(22):3727-34. PubMed ID: 18669459
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive value of estrogen receptor status as assessed by ligand-binding assay in patients with early-stage breast cancer treated with breast conserving surgery and radiation therapy.
    Takei H; Horiguchi J; Maemura M; Koibuchi Y; Oyama T; Yokoe T; Iino Y; Morishita Y
    Oncol Rep; 2002; 9(2):375-8. PubMed ID: 11836611
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ovarian ablation or suppression in premenopausal early breast cancer: results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial.
    Adjuvant Breast Cancer Trials Collaborative Group
    J Natl Cancer Inst; 2007 Apr; 99(7):516-25. PubMed ID: 17405996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunohistochemical detection of hormone receptors in breast carcinomas (ER-ICA, PgR-ICA): prognostic usefulness and comparison with the biochemical radioactive-ligand-binding assay (DCC).
    Beck T; Weikel W; Brumm C; Wilkens C; Pollow K; Knapstein PG
    Gynecol Oncol; 1994 May; 53(2):220-7. PubMed ID: 8188083
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The role of tumor receptor status in choosing adjuvant therapy for breast cancer patients of reproductive age].
    Samgina AA; Letiagin VP; Kuz'mina ZV
    Vopr Onkol; 1992; 38(7):780-7. PubMed ID: 1300782
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estrogen receptor determination and long term survival of patients with carcinoma of the breast.
    Crowe JP; Gordon NH; Hubay CA; Shenk RR; Zollinger RM; Brumberg DJ; McGuire WL; Shuck JM
    Surg Gynecol Obstet; 1991 Oct; 173(4):273-8. PubMed ID: 1925896
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays.
    Albain KS; Paik S; van't Veer L
    Breast; 2009 Oct; 18 Suppl 3():S141-5. PubMed ID: 19914534
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 81.